,i #aagth ,,congress #b;d ,session ,h4 ,r4 #fhge ,,in ,,the ,,house ,,of ,,representatives ,february #bh1 #bjbb,mr4 ,swalwell 7for himself and ,mr4 ,emmer7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to update the ,national ,action ,plan for ,adverse ,drug ,event ,prevention to provide educational information on adverse drug events and pharmacogenomic testing1 to improve electronic health records for pharmacogenomic information1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,right ,drug ,dose ,now ,act4 #b4 ,table of contents ,the table of contents of this ,act is as follows3 ,sec4 #a4 ,short title4,sec4 #b4 ,table of contents4,sec4 #c4 ,national ,action ,plan for ,adverse ,drug ,event ,prevention4,sec4 #d4 ,adverse drug event and pharmacogenomic testing awareness4,sec4 #e4 ,improving ,,ehr systems to improve the use of pharmacogenomic information4,sec4 #f4 ,increased authorization for pharmacogenomics implementation research4,sec4 #g4 ,definition4 #c4 ,national ,action ,plan for ,adverse ,drug ,event ,prevention ,the ,secretary of ,health and ,human ,services shall-- 7#a7 not later than #ahj days after the date of enactment of this ,act1 in coordination with the heads of other relevant ,federal departments and agencies including the ,director of the ,national ,human ,genome ,research ,institute1 and in consultation with the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 the ,director of the ,national ,center for ,biotechnology ,information1 and the ,director of the ,national ,library of ,medicine1 submit a report to the ,congress on-- 7,a7 the implementation of the ,national ,action ,plan for ,adverse ,drug ,event ,prevention of the ,department of ,health and ,human ,services2 and 7,b7 the progress in meeting the target approved by the ,federal ,interagency ,steering ,committee for ,adverse ,drug ,events for a #aj-percent reduction for-- 7i7 the rate of adverse drug events from anticoagulants among ,united ,states inpatient stays2 7ii7 the rate of adverse drug events from hypoglycemic agents among ,united ,states inpatient stays2 7iii7 the rate of adverse drug events from opioid analgesics among ,united ,states inpatient stays2 7iv7 the rate of visits to ,united ,states hospital emergency departments for adverse drug events associated with injury from oral anticoagulants2 7v7 the rate of visits to ,united ,states hospital emergency departments for adverse drug events associated with injury from insulin2 and 7vi7 the rate of visits to ,united ,states hospital emergency departments for adverse drug events associated with therapeutic use of opioid analgesics2 7#b7 convene the ,federal ,interagency ,steering ,committee for ,adverse ,drug ,events to update the ,national ,action ,plan for ,adverse ,drug ,event ,prevention2 and 7#c7 require such ,committee1 in updating the ,national ,action ,plan for ,adverse ,drug ,event ,prevention-- 7,a7 to consider advances in scientific understanding and technology pertaining to drug-gene-drug interactions1 clinical outcomes1 health care utilization1 and the decreasing cost of genetic testing2 7,b7 to assess the role of pharmacogenetics testing combined with clinical decision support as an evidence-based prevention tool2 and 7,c7 to evaluate operating characteristics for ,federal adverse drug event surveillance systems and expand capabilities to identify genetic associations in adverse events4 #d4 ,adverse drug event and pharmacogenomic testing awareness ,part ,p of title ,,iii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhj;g et seq47 is amended by adding at the end the following3 #cii,v-#g4 ,adverse drug event and pharmacogenomic testing awareness 7a7 ,public ,education ,campaign 7#a7 ,in general ,the ,secretary1 acting through the ,director of the ,national ,human ,genome ,research ,institute1 in consultation with the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 the ,director of the ,national ,center for ,biotechnology ,information1 and the ,director of the ,national ,library of ,medicine1 shall conduct a national evidence-based education campaign to increase the public's awareness regarding-- 7,a7 the prevalence of adverse drug events and adverse drug reactions2 7,b7 specific risk factors that increase an individual's likelihood of experiencing an adverse drug event or adverse drug reaction2 7,c7 basic information about pharmacogenomic testing and how its use1 including incorporation in comprehensive medication management1 may prevent adverse drug reactions in certain clinical situations2 7,d7 the role of health care providers in performing pharmacogenomic testing1 interpreting the results of such testing1 and adjusting medications based on such results2 7,e7 the availability of pharmacogenomic testing2 7,f7 comprehensive medication management2 and 7,g7 how the benefits of an individual's pharmacogenomic test results might change or be relevant over time4 7#b7 ,consideration of advice of stakeholder experts ,the education campaign under paragraph 7#a7 shall take into consideration the advice of stakeholder expects1 such as those specializing in medical genetics and pharmacogenetics and collaborative communities focused on pharmacogenomics4 7#c7 ,media campaign ,in conducting the education campaign under paragraph 7#a71 the ,secretary1 after considering the advice of stakeholder experts pursuant to paragraph 7#b71 may award grants or contracts to entities to establish national multimedia campaigns that may include advertising through television1 radio1 print media1 billboards1 posters1 all forms of existing and especially emerging social networking media1 other ,internet media1 and any other medium determined appropriate by the ,secretary4 7#d7 ,rural regions1 health professional shortage areas1 and underserved communities ,the ,secretary shall ensure that the education campaign under paragraph 7#a7-- 7,a7 reaches rural and medically underserved communities 7as defined in section #gii72 and 7,b7 includes the involvement of community health centers1 community pharmacies1 and other local health clinics4 7b7 ,health care professional education campaign 7#a7 ,in general ,the ,secretary1 acting through the ,director of the ,national ,human ,genome ,research ,institute1 in consultation with the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 the ,director of the ,national ,center for ,biotechnology ,information1 the ,director of the ,national ,library of ,medicine1 and the ,administrator of the ,health ,resources and ,services ,administration1 shall establish a national health education program for health care providers and health care leaders1 including administrators1 pharmacists1 nurse practitioners1 physicians' assistants1 physician medical geneticists1 laboratory medical geneticists1 genetic counselors1 medical educators1 and the faculty of schools of medicine and other schools of health professions1 on the following3 7,a7 ,pharmacogenomic testing and the extent of its ability to prevent adverse drug reactions4 7,b7 ,pharmacogenomic testing1 drug interaction alerting systems1 when to refer to or consult with a genetics provider1 and the standards of care for patients who are suspected or known to have a genetic variant that is known to impact drug metabolism4 7,c7 ,evidence-based information that would encourage individuals and their health care professionals to consider pharmacogenomic testing as part of their health care plan to the extent appropriate4 7,d7 ,the role of medical professionals who specialize in genetics and genomics4 7,e7 ,how to incorporate pharmacogenomics into comprehensive medication management4 7#b7 ,grants 7,a7 ,award ,in carrying out the national health education program under this subsection1 the ,secretary1 acting through the ,director of the ,national ,human ,genome ,research ,institute1 may award grants to nonprofit organizations to carry out educational activities with respect to the topics listed in subparagraphs 7,a7 through 7,d7 of paragraph 7#a74 7,b7 ,use of funds ,a grant under subparagraph 7,a7 may be used to support one or more of the following activities3 7i7 ,increasing the knowledge and awareness of health care providers and health care leaders about pharmacogenomic testing and drug interactions4 7ii7 ,increasing the number of health professional schools that incorporate pharmacogenomic curricula in classroom instruction4 7iii7 ,increasing the ability of health care providers to note and respond to the impact of gender1 ethnicity1 age1 and other relevant characteristics on drug metabolism4 7iv7 ,developing principles1 practices1 and curriculum instruction that prepare medical1 nursing1 pharmacy1 and other health professions students to effectively apply knowledge and skills needed to recognize-- 7,i7 when a patient is eligible for pharmacogenomic testing1 including as part of comprehensive medication management when appropriate1 and in accordance with the patient's health care team1 a drug product's label1 and professional clinical guidelines2 and 7,,ii7 how to appropriately use the test results to adjust a prescription or otherwise change a patient's health care plan4 7v7 ,providing opportunities for practicing health care professionals to receive pharmacogenomics training and education through a variety of modalities including in-person1 electronic media1 professional meetings and conferences1 and social media4 7c7 ,reporting ,at least every three years1 the ,secretary1 acting through the ,director of the ,national ,human ,genome ,research ,institute1 in consultation with the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 the ,director of the ,national ,center for ,biotechnology ,information1 the ,director of the ,national ,library of ,medicine1 the ,administrator of the ,centers for ,medicare ,medicaid ,services1 and relevant stakeholders with expertise in developing quality measures of label and peer-reviewed professional guidelines on drug-gene interactions1 shall publish data on-- 7#a7 the public's awareness regarding adverse drug events and pharmacogenomic testing2 7#b7 the number or percentage of individuals utilizing information to inform their health care decisions regarding prescription medications and pharmacogenomic testing2 7#c7 the change in the number or percentage of individuals enrolled in a prescription drug plan under part ,d of the title ,,xviii of the ,social ,security ,act receiving a pharmacogenetic test1 as recommended in alignment with a drug product's label or peer-reviewed professional guidelines2 and 7#d7 the number or percentage of changes1 beginning one year after the date of enactment of this section1 in medication management as a result of incorporating information from pharmacogenomic testing4 7d7 ,definitions ,in this section3 7#a7 ,adverse drug event ,the term adverse drug event means an injury resulting from any medical intervention with a drug4 7#b7 ,adverse drug reaction ,the term adverse drug reaction means a response to a drug that-- 7,a7 is noxious and unintended2 and 7,b7 occurs at doses normally used in humans for prophylaxis1 diagnosis1 or therapy of disease or for the modification of physiologic function4 7e7 ,authorization of ,appropriations ,to carry out this section1 there is authorized to be appropriated #ej1jjj1jjj for each of fiscal years #bjbb through #bjbg4 4 #e4 ,improving ,,ehr systems to improve the use of pharmacogenomic information 7a7 ,certification criteria ,the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary7 shall adopt pursuant to subtitle ,a of title ,,xxx of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;jj-#aa et seq47 certification criteria for health information technology1 including for electronic prescribing systems and real-time pharmacy benefit checks1 such that before a medication order is completed and acted upon during computerized provider order entry1 interventions must automatically indicate to a user-- 7#a7 when pharmacogenomic testing is appropriate based on a drug product's label or peer-reviewed professional guidelines2 and 7#b7 drug-gene and drug-drug-gene associations1 established by a drug product's label or peer-reviewed professional guidelines1 based on a patient's medication list1 medication allergy list1 and results from pharmacogenomic testing4 7b7 ,reporting and association of adverse drug events ,the ,secretary1 in consultation with the ,commissioner of ,food and ,drugs1 shall carry out a program to improve the reporting of adverse drug events and the association1 if any1 of such events to a patient's genetic status4 ,as part of the program1 the ,secretary shall issue regulations pursuant to the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 and other applicable statutory authorities to-- 7#a7 ensure that drug-gene interaction alerting systems are continuously updated to incorporate information from new or updated drug labels with pharmacogenomic information and newly established peer-reviewed professional guidelines on drug-gene associations2 7#b7 facilitate the reporting of adverse drug events to the ,,fda ,adverse ,event ,reporting ,system directly through the use of the health care provider's electronic health record system2 and 7#c7 allow for the reporting of whether an adverse drug event is caused by pharmacogenetic interactions to the ,,fda ,adverse ,event ,reporting ,system directly through the use of the health care provider's electronic health record system4 7c7 ,updating ,,faers2 patient-,friendly reporting ,the ,secretary1 acting through the ,commissioner of ,food and ,drugs1 shall-- 7#a7 update the ,,fda ,adverse ,event ,reporting ,system1 including to-- 7,a7 accept information directly from health care providers' electronic health record systems2 7,b7 improve the collection of real world evidence 7as defined in section #eje;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;g772 and 7,c7 create a selection tool that allows individuals to report whether an adverse drug event is associated with a drug-gene interaction2 7#b7 work with relevant ,federal agencies and offices1 and stakeholders1 to create patient-friendly electronic options for reporting adverse drug events such as submission through a designated mobile device application or mobile device messaging application2 and 7#c7 not later than #a year after the date of enactment of this ,act1 report to the ,congress on the progress made in implementing paragraphs 7#a7 and 7#b74 7d7 ,assessment on additional improvements to electronic health record systems 7#a7 ,in general ,not later than #ahj days after the date of enactment of this ,act1 the ,secretary shall-- 7,a7 complete an assessment on additional improvements to electronic health record systems that are needed to further the development of real world evidence 7as defined in section #eje;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;g77 in pharmacogenomics2 and 7,b7 submit a report to the ,congress on the findings on the assessment4 7#b7 ,consideration of needed advancements ,as part of the assessment under paragraph 7#a71 the ,secretary shall consider what advancements are needed to capture information about the laboratory and the test used as part of pharmacogenomic testing4 #f4 ,increased authorization for pharmacogenomics implementation research ,there is authorized to be appropriated to the ,national ,institutes of ,health #g1jjj1jjj for each of fiscal years #bjbb through #bjbe for the conduct1 support1 and maintenance of pharmacogenomics implementation research through the ,genomic ,community ,resources program4 #g4 ,definitions ,in this ,act3 7#a7 ,the term adverse drug event means an injury resulting from any medical intervention with a drug4 7#b7 ,the term comprehensive medication management means medication management pursuant to a standard of care that ensures each patient's medications are individually assessed to determine that each medication is appropriate for the patient1 effective for the medical condition1 and safe given the comorbidities and other medications being taken and able to be taken by the patient as intended4